drugset / Trial / NCT02171546
Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
Part 1: To investigate the effect of quinidine, a P-glycoprotein (P-gp) probe inhibitor on the bioavailability of dabigatran etexilate, Part 2: To determine the effect of quinidine on the bioavailability of fexofenadine, a probe substrate for P-gp
Timeline
- Start
- 2007-11
- Primary completion
- 2008-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 150 mg | — |
| Subject | Fexofenadine | Unknown | — | — |
| Subject | Quinidine | Small molecule | 600 mg | — |
Indications
No indication recorded.